FY2028 EPS Forecast for Alto Neuroscience Lowered by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – William Blair decreased their FY2028 earnings estimates for Alto Neuroscience in a report issued on Tuesday, October 22nd. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($3.26) for the year, down from their prior forecast of ($3.16). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.63) per share.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07.

Several other equities analysts also recently weighed in on ANRO. Robert W. Baird reduced their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $29.00 to $4.00 in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.40.

Alto Neuroscience Trading Down 0.2 %

ANRO opened at $4.12 on Friday. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $12.12 and a 200-day moving average price of $12.43. Alto Neuroscience has a twelve month low of $4.04 and a twelve month high of $24.00.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers bought a new stake in Alto Neuroscience during the second quarter valued at approximately $113,000. Federated Hermes Inc. lifted its position in Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after purchasing an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Alto Neuroscience during the second quarter valued at approximately $252,000. University of Texas Texas AM Investment Managment Co. bought a new stake in Alto Neuroscience during the first quarter valued at approximately $340,000. Finally, Bowie Capital Management LLC bought a new stake in Alto Neuroscience during the second quarter valued at approximately $462,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.